Challenges of CART cell-based cancer immunotherapy directed against solid tumors / 中国免疫学杂志

Chimeric antigen receptor T cell therapy in the CD19+blood system of malignant tumor has achieved astonishing re-sults.Targeting the CART CD19 cells can increase the remission rate of acute lymphoblastic leukemia.But the curative effect of CART therapy for solid tumors in recent years has been no substantive breakthrough.There are many problems to be solved in tumor immunotherapy of solid tumor.For example,how CART break through into solid tumor microenvironment and keep vitality,how to identify cancer cells accurately and how to surmount immunosuppression playing an effective role.We here discuss that targeting CART cells toward solid tumors faces certain circumstances critical for the therapeutic success.